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Abstract. The objective of the present study was to deter-
mine whether the development of behavioral sensitiza-
tion to apomorphine could be blocked by either D1 or 
D2 selective dopamine antagonists. In three experiments, 
male rats received IG--21 daily injections of a selective D 1 
(SCH 23390; 0 or 0.5 mg/kg IP) or D2 (sulpiride; 0, 30, 
or 100 mg/kg IP) antagonist followed by an apomor-
phine (0 or l.O mg/kg SC) injection. In two experiments, 
the rats were tested for locomotor activity in photocell 
arenas after the daily injections. In all experiments, the 
rats were tested for sensitization to apomorphine follow-
ing the training phase. The results indicated that apo-
morphine produced a progressively greater increase in 
locomotor activity with each injection, and this apo-
morphine-induced increase in activity was completely 
blocked by both sulpiride and SCH 23390 treatments. 
However, although both sulpiride and SCH 23390 
blocked apomorphine-induced activity, only SCH 23390 
injections prevented the development of sensitization to 
apomorphine. That is, rats pretreated with sulpiride 
and apomorphine displayed significant sensitization 
when subsequently tested with a challenge dose of apo-
morphine alone. These findings suggest that the develop-
ment of behavioral sensitization to apomorphine is re-
lated specifically to the stimulation of dopamine D 1 re-
ceptors. 
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The acute administration of direct (e.g., apomorphine) 
and indirect (e.g., amphetamine, cocaine) dopamine ag-
onists in rats often produces an increase in locomotor 
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activity and the induction of various stereotyped oral 
movements (sniffing, licking, and gnawing). The repeated 
administration of these drugs results in the development 
of behavioral sensitization, characterized by a progres-
sive augmentation of these drug-induced motor behav-
iors. In humans, repeated exposure to drugs which direct-
ly or indirectly stimulate dopamine receptors often re-
sults in the delayed appearance of several severe, and 
sometimes long-lasting, behavioral side-effects (e.g., am-
phetamine psychosis). It is widely assumed that the 
neurobiological mechanisms mediating behavioral sen-
sitization in animals are the same as those responsible for 
the side-effects observed in humans (see Robinson and 
Becker 1986; Kalivas and Weber 1988). Although it is 
clear that the development of behavioral sensitization 
requires the stimulation of dopamine receptors (Ku-
czenski and Leith 1981; Mattingly and Rowlett 1989; 
Peris and Zahniser 1989), the specific drug-induced neu-
robiological changes mediating the development of be-
havioral sensitization are unknown. 
Dopamine receptors exist in at least two distinct 
subtypes possessing unique pharmacologic and biochem-
ical properties (see Breese and Creese 1986; Clark and 
White 1987, for review). Dopamine D 1 receptors stimu-
late adenylate cyclase activity, whereas dopamine 0 2 
receptors are either unlinked to, or inhibit, this enzyme. 
Dopamine agonists which induce behairioral sensitiza-
tion (e.g., apomorphine, amphetamine, cocaine) result in 
an increased stimulation of both D 1 and 0 2 dopamine 
receptor subtypes. At present, there is still considerable 
disagreement regarding the involvement bf specific dopa-
mine receptor subtypes in the developme'nt of behavioral 
sensitization. For example, Stewart an~ Vezina (1989; 
Vezina and Stewart 1989) have conclu~ed that the de-
velopment of sensitization to amphetamine is the result 
of increased D 1 receptor stimulation, whereas Levy et al. 
(1988) suggest that amphetamine-induced sensitization is 
the result of 0 2 receptor stimulation. In contrast, there 
is some evidence which suggests that the toncurrent stim-
ulation of both 0 1 and 0 2 receptors niay be necessary 
for the development of sensitization to cocaine (Peris and . 
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Zahniser 1989) and methamphetamine (Ujike et al. 
1989). Thus, although the overt behavioral effects of 
these indirect dopamine agonists are similar, the 
neurochemical mechanisms mediating the development 
of behavioral sensitization to these agents may differ. 
The objective of the present study was to determine 
the involvement of specific dopamine receptor subtypes 
in the development of behavioral sensitization to the 
direct dopamine receptor agonist, apomorphine. Conse-
quently, in three experiments rats were treated daily with 
apomorphine in combination with either a selective D 1 
or D2 antagonist and then tested for sensitization follow-
ing a challenge dose of apomorphine. 
Experiment 1 
Repeated apomorphine treatments in doses equal to or 
greater than LO mg/kg produce a progressively greater 
increase in locomotor activity when administered inter-
mittently (Castro et al. 1985; Mattingly et al. 1988a, 
1988b). This progressive increase occurs regardless of 
whether the apomorphine injection is paired with the 
activity testing environment, but is generally larger if 
such pairing occurs (Mattingly and Gotsick 1989). More-
over, the development of sensitization to apomorphine 
is completely blocked by the concurrent administration 
of the mixed D,/D2 dopamine receptor antagonist, halo-
peridol (Mattingly and Rowlett 1989). The purpose of 
experiment l, therefore, was to determine. whether the 
development of sensitization to apomorphine would also 
be prevented by concurrent administration of the selec-
tive D2 dopamine receptor antagonist, sulpiride. 
Materials and methods 
Subjects. Seventy-two male Wistar albino rats (Harlan Industries, 
Indianapolis, IN) weighing between 250 and 300 g served as sub-
jects. All rats were housed individually in a colony room with a 12-h 
light-dark cycle and maintained with food and water available 
continuously. All behavioral testing was conducted during the light 
phase of the cycle. 
Apparatus. Activity measures were taken in two BRS/Lehigh Valley 
cylindrical activity drums (Model 145--03) that were 60 cm in dia-
meter and 43 cm high. The interior of each drum was painted Hat 
black, and the floor was made of 4 cm diamond-shaped wire mesh. 
Each drum was located in a separate sound-attenuated experimen-
tal cubicle that was kept totally dark throughout testing. 
Two banks of three infrared photocells were mounted on the 
outside of each drum. The photocells \Vere approximately 12 cm 
apart and 2.5 cm above the drum floor. The photocell banks were 
connected to back-path eliminator diodes. Movement of the rat 
through a photocell beam sent a single pulse to the counters. Simul-
taneous pulses (i.e., pulses spaced less than 0.05 s apart) such as 
might occur when two beams are broken near their intersection 
were recorded as a single count by this method. Thus, activity was 
operationalized as the cumulative number of photobeam interrup-
tions per unit time. 
Drugs. Apomorphine hydrochloride (Sigma) was dissolved daily in 
0.001 N HCL. It was injected SC in a volume of0.5 ml/kg. Sulpiride 
(Sigma) was mixed daily in a I% glacial acetic acid solution and 
administered IP in a volume of 1.0 ml/kg. Control injections were 
given using the appropriate vehicle using the same route and volume 
as the corresponding drug injection. 
Design and procedure. At the beginning of the experiment, the rats 
were randomly assigned, in equal numbers, to one of six groups 
comprising a two (agonist dose) x three (antagonist dose) factorial 
design. On each of the first 21 days of the experiment each rat was 
first injected with either 0 (vehicle), 30, or 100 mg/kg sulpiride and 
then about 30 min later injected with either 0 (vehicle) or 1.0 mg/kg 
apomorphine. The rats were returned to their home cage after the 
daily injections without behavioral testing. Fol1owing this training 
phase the rats were left undisturbed in their home cages for 6 days 
prior to sensitization testing. On each of the 4 sensitization test 
days, all rats received an injection ofapomorphine (5.0 mg/kg) prior 
to activity testing. Activity testing began 15 min following the injec-
tion and was conducted for 20 min. 
Results and discussion 
The results of the sensitization test phase are shown in 
Fig. I. These data were analysed with a three-factor 
mixed analysis of variance (ANOV A) using antagonist 
dose and agonist dose as between factors and activity 
session as a within factor. As may be seen in Fig. 1, the 
three groups of rats pretreated with apomorphine (VEH-
APO, 30 SUL-APO, 100 SUL-APO) for 21 days dis-
played a much greater increase in activity in response to 
apomorphine than did rats receiving apomorphine for 
the first time (VEH-VEH, 30 SUL-VER, 100 SUL-
VEH), agonisteffect, F(l, 66) = 17.12, P<0.0001. More 
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Fig. 1. 'Mean activity counts across four 20 min sensitization test 
sessions for rats chronically pretreated with sulpiride (0 (VEH), 30, 
or 100 mg/kg SUL) and apomorphine (0 (YEH) or 1.0 mg/kg, 
APO). All rats received 5.0 mg/kg apomorphine 15 min before 
each test session. •-• 100 SUL-APO; 0- - -O 100 SUL-YEH; 
"-" 30 SUL-APO; 6- - -6 30 SUL-YEH; •-• YEH-APO; 
0---0 YEH-YEH 
concurrent sulpiride treatments. That is. the apomor-
phine-induced activity response of rats pretreated with 
sulpiride and apomorphine did not differ from that of 
rats pretreated with only apomorphine (i.e., VEH-APO 
group). Likewise, it is clear from Fig. 1 that repeated 
treatmen.ts of sulpiride without apomorphine did not 
significantly affect subsequent sensitivity to apomor-
phine in this test. The ANOV A performed on these data 
indicated that neither the main effect of antagonist dose 
nor the Antagonist dose x Agonist dose interaction was 
significant. The main effect of test session, however, was 
significant [F(3, 198) = 120.68, P<0.0001], as all groups 
displayed a progressively greater increase in activity in 
response to apomorphine across the four test sessions. 
Experiment 2 
In experiment 1, rats pretreated with apomorphine dis-
played significant sensitization and this sensitization was 
not blocked by the D 2 antagonist sulpiride. From the 
results of experiment I, however, we have absolutely no 
evidence that sulpiride was effective in blocking dopa-
mine receptors. The purpose of experiment 2, therefore, 
was to systematically replicate experiment I and to deter-
mine the acute effect of sulpiride on apomorphine-
induced locomotor activity. Consequently, four groups 
of rats were injected daily with sulpiride and/or apomor-
phine and tested for locomotor activity for 7 days. Fol-
lowing this brief subchronic training phase, all rats were 
tested for activity following an apomorphine injection 
for four additional days. Experiment 2 differed from 
experiment I in the following ways: I) only the 
I 00 mg/kg dose of sulpiride was used; 2) the rats were 
tested for activity during the training phase; 3) the train-
ing phase was only conducted for 7 days; and 4) a 
1.0 mg/kg dose of apomorphine was used in both the 
training phase and the sensitization test phase. 
Materials and methods 
Subjects, apparatus, and drugs. The subjects were 35 male Wistar 
albino rats (Harlan Industries, Indianapolis, IN) experimentally 
naive and weighing between 250 and 350 g at the beginning of the 
experiment. They were housed and maintained as in experiment I. 
The photocell activity drums used were also the same as in experi-
ment 1. Like,vise, the drugs were obtained, prepared, and adminis-
tered as in experiment 1. 
Design and procedure. The rats \Vere randomly assigned to one of 
four groups {n=8-9 each) comprising the 2 (antagonist dose: 0 or 
IOO mg/kg sulpiride) x 2 (agonist dose: 0 or 1.0 mg/kg apomor-
phine) factorial design. On day 1 of the training phase each rat was 
first injected IP with either sulpiride or vehicle and returned to its 
homecage. Thirty minutes later apomorphine or vehicle was inject-
ed SC and the animal was again returned to its homecage. Fifteen 
minutes follo\ving the second injection each rat was placed in the 
activity drum and activity was measured for 20 min. This injection-
test procedure was repeated daily for 7 days. Sensitization testing 
began 24 h after the last training day and was conducted for 4 days. 
On each of these days all rats were tested for locomotor activity 
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Fig. 2. Mean activity counts across the training (l-7) and sensitiza-
tion test (8-11) sessions for rats pretreated with 100 mg/kg sulpiride 
(JOO SUL) or vehicle (VEH) and 1.0 mg/kg apomorphine (APO) or 
VEH. All rats received a single injection of 1.0 mg/kg APO prior 
to each sensitization test session. For symbols see legend of Fig. l 
Results and discussion 
Training sessions 1-7. The mean activity counts for the 
groups during the training phase (sessions 1-7) are 
shown in the left panel of Fig. 2. As shO\yn in this figure, 
rats injected with apomorphine only (YEH-APO) dis-
played a progressively greater increase in locomotor ac-
tivity across the 7 test days and were more active than 
control rats (VEH-VEH) across sessions 4-7. In contrast, 
rats treated with sulpiride only (! 00 SULc VEH) were less 
active than control rats across the seven sessions. More 
important, as may seen in Fig. 2, sulpiride given concur-
rently with apomorphine completely blocked the activity 
increasing effect of repeated apomorphine treatments. 
Indeed, the activity of rats given sulpiriOe and apomor-
phine (100 SUL-APO) appeared compi\rable to that of 
the vehicle control rats (VEH-VEH) across sessions 3-7. 
As expected from inspection of Fig. 2, the mixed factor 
ANOV A performed on these data rev~aled significant 
main effects of agonist dose, antagonist dose, and a 
significant Agonist x Antagonist x Day interaction 
[F(l, 31)=9.89, P<O.Ol, F(l, 31)=36.22, P<0.0001, 
and F(6, 186)=4.72, P<0.001, respectively]. 
' 
Sensitization test sessions 8-11. As may he seen in Fig. 2, 
rats pretreated with sulpiride for 7 days increased activity 
on session 8 when given only an apombrphine injection. 
This increase, however, was greater forjsulpiride-treated 
rats which had also received apomorphil)e pretreatments. 
Indeed, the rats given concurrent sulpiride-apomorphine 
(100 SUL-APO) pretreatments were as ltctive on session 
8 as rats given only apomorphine (VEH1APO) during the 
training phase. In contrast, rats pretreated with only 
sulpiride (100 SUL-VEH) increased activity to a level 
comparable to that of the vehicle control rats (VEH-
VEH) on session 8. The hyperactivit~ of the apomor-
phine pretreated rats was maintained across sessions 
' 
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9-11 even though the rats pretreated with vehicle 
(100 SUL-YEH, YEH-YEH) progressively increased ac-
tivity across these sessions as they too became more 
sensitive to apomorphine. These findings suggest that 
concurrent sulpiride treatments did not block the de-
velopment of behavioral sensitization to apomorphine. 
Consistent with this interpretation, the mixed factor 
ANOY A performed on the activity counts across ses-
sions 8-11 revealed only a significant main effect of 
agonist and a significant main effect of session 
[F(l, 31)= 9.51, P< 0.01, and F(3, 93) = 14.71, P< 0.0001, 
respectively]. Neither the main effect of antagonist nor 
any of the interactions containing antagonist as a factor 
were significant. 
Experiment 3 
It is evident from the results of experiment 2 that the D 2 
antagonist sulpiride blocks the progressive increase in 
locomotor activity induced by repeated treatments with 
the mixed dopamine receptor agonist apomorphine. 
However, consistent with experiment I, the results of 
experiment 2 clearly indicate that sulpiride does not 
prevent the development of behavioral sensitization to 
apomorphine. In contrast, concurrent treatment with 
the mixed D 1/D2 dopamine antagonist haloperidol com-
pletely blocks the development of sensitization to apo-
morphine (Mattingly and Rowlett 1989). Taken togeth-
er, these results suggest that the development of behav-
ioral sensitization to apomorphine is either exclusively 
related to the stimulation of D 1 dopamine receptors, or 
that repeated stimula\ion of either D1 or D 2 receptors 
might be sufficient to induce sensitization. The purpose 
of experiment 3, therefore, was to determine whether the 
development of behavioral sensitization to apomorphine 
could be prevented by a selective blockade of dopamine 
D 1 receptors. Consequently, four groups of rats were 
injected daily with apomorphine and/or the selective D 1 
dopamine receptor antagonist SCH 23390 and tested for 
changes in locomotor activity. The design and procedure 
was the same as in experiment 2, except SCH 23390 
rather than sulpiride was used. 
Materials and methods 
Subjects, design and procedure. Forty male Wistar albino rats (Har-
lan Industries, Indianapolis, IN) weighing between 250 and 350 g 
served as subjects. The rats were randomly assigned, in equal num-
bers, to one of four training groups comprising the 2 (antagonist 
dose: 0 or 0.5 mg/kg SCH 23390, Research Biochemicals) x 2 (ag-
onist dose: 0 or 1.0 mg/kg apomorphine) factorial design. The 
apparatus and procedure was the same as in experiment 2. SCH 
23390 was dissolved daily in distilled H20 and injected IP in a 
volume of 1.0 mlfkg. Apomorphine was obtained, prepared, and 
administered as described previously. 
Results and discussion 
Training sessions 1-7. The mean activity counts of the 
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Fig. 3. Mean activity counts across the training (I-7) and sensitiza-
tion test (8-11) sessions for rats pretreated with 0.5 mg/kg SCH 
23390 (SCH) or vehicle (VEH) and 1.0 mg/kg apomorphine (APO) 
or YEH. All rats received a single injection of 1.0 mg/kg APO prior 
to each sensitization test session. •-• SCH-APO; D- -D SCH-
VEH; •-• VEH-APO; 0---0 VEH-VEH 
sented in Fig. 3. As shown in this figure, repeated apo-
morphine treatments alone (YEH-APO group) resulted 
in a progressively greater increase in activity with each 
injection. This progressive increase in apomorphine-
induced activity, however, was completely blocked by 
concurrent SCH 23390 treatments (see SCH-APO 
group). Indeed, SCH 23390 treatments greatly depressed 
activity compared to the vehicle control group (VEH-
YEH), regardless of whether apomorphine was also 
given (see SCH-YEH, SCH-APO groups). As expected, 
the three-factor mixed ANOY A performed on these data 
revealed significant main effects of agonist dose, an-
tagonist dose and a significant Agonist x Antagonist in-
teraction [F(l, 36) = 5.27, P< 0.05, F(l, 36) = 110.56, 
P<0.0001, and F(l, 36)=9.21, P<0.01, respectively]. 
The session effect was also significant [F(6, 216)=4.01, 
P< 0.001], as was the Agonist x Session [F(6, 216)= 19.58, 
P< 0.0001], and the Agonist x Antagonist x Session 
interaction [F(6, 216)=9.06, P<0.0001. These signifi-
cant interactions reflect the fact that only the YEH-APO 
groups displayed a significant increase in activity across 
the seven sessions, and the activity level of the YEH-APO 
group did not increase above that of the YEH-YEH 
control group until the third activity test session. 
Sensitization test sessions 8-11. As may be seen in Fig. 3, 
the SCH 23390-pretreated rats (SCH-YEH, SCH-APO) 
increased activity on session 8, when given only an injec-
tion of apomorphine, to a level comparable to that of rats 
previously treated only with vehicle (YEH-YEH). More-
over, this increase was the same for both SCH 23390 
pretreatment groups. That is, rats pretreated with apo-
morphine and SCH 23390 (SCH-APO) during the train-
ing phase were no more sensitive to apomorphine on 
session 8 than rats pretreated with only SCH 23390 
(SCH-YEH). In other words, concurrent SCH 23390 
treatments along with apomorphine completely blocked 
the development of sensitization to apomorphine. The 
mixed factor ANOV A performed on the mean activity 
counts across these four sensitization test sessions 
indicated a significant main effect of antagonist 
[F(l, 36) = 5.73, P < 0.05] and a significant Antagonist x 
Agonistinteraction [F(l, 36)=5.98, P<0.05]. This latter 
interaction was further analysed using a Newman-Keuls 
post hoc test to compare the mean activity counts of the 
four groups collapsed across the four sensitization test 
sessions. The results of this analysis indicated that over-
all, the rats pretreated with only apomorphine (VEH-
APO) during the training phase were significantly more 
active than the other three pretreatment groups [P< 0.05 
in each case]. In contrast, this analysis indicated that 
overall, the rats pretreated with SCH 23390 and apomor-
phine (SCH-APO) were significantly less active than the 
other three groups [P< 0.05 in each case]. The apomor-
phine-induced activity level of rats pretreated with only 
SCH 23390 (SCH-YEH) did not differ across these ses-
sions from that of the rats pretreated with only vehicle 
(VEH-VEH). 
The ANOV A performed on these data also revealed 
a significant session effect [F{3, 108)= 19.23, P<0.0001], 
as overall, the rats tended to increase activity across 
sessions. This increase, however, was greater for rats 
receiving apomorphine for the first time than for rats 
which were pretreated with apomorphine [Agonist x 
Session interaction, F(3, 108) = 8.58, P < 0.01]. 
In summary, the results of experiment 3 indicate that 
SCH 23390 significantly depressed locomotor activity in 
control rats and acutely blocked the activity-increasing 
effect of repeated apomorphine treatments. More impor-
tant, concurrent SCH 23390 treatments completely 
prevented the development of behavioral sensitization to 
apomorphine. 
Discussion 
It is evident from the present results that repeated treat-
ment of rats with the direct dopamine receptor agonist, 
apomorphine, results in the development of behavioral 
sensitization. This finding is consistent with previous 
work (e.g., Castro et al. 1985; Mattingly et. al 1988b). 
Further, the results of the present experiments clearly 
indicate that the activating effects of apomorphine on 
locomotor activity may be blocked by concurrent treat-
ment with either a selective D 1 or D 2 antagonist. In 
experiment 2, the D2 antagonist, sulpiride, blocked the 
effects of apomorphine on locomotor activity, and in 
experiment 3, the activity-increasing effects of apomor-
phine were prevented by the selective D 1 antagonist SCH 
23390. Taken together, these findings suggest that the 
concurrent stimulation of both D 1 and D 2 dopamine 
receptors is neccessary for the expression of apomor-
phine-induced locomotor activity. Consistent with these 
results, recent evidence suggests that the expression of 
other dopamine agonist-induced behavioral and elec-
trophysiological effects also requires the concomitant 
stimulation of both D 1 and D 2 dopamine receptors 
(Amalric et al. 1986; Carlson et al. 1987; Plaznik et al. 
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1989; Ross et al. 1989; Bergman et al. 1990; Moore and 
Axton 1990). 
In contrast to the involvement of both D 1 and D 2 
receptors in the expression of apomorphine-induced 
locomotor activity, the development of behavioral sen-
sitization to apomorphine appears to require the re-
peated stimulation of only the D 1 receptor. Indeed, in 
both experiments 1 and 2, the concurrent administration 
of the selective D2 antagonist, sulpiride, in doses which 
blocked apomorphine-induced increases in activity, did 
not prevent the development of behavioral sensitization. 
That is, rats pretreated daily with sulpiride and apomor-
phine combined displayed an enhanced locomotor activ-
ity response to a challenge dose ofapomorphine compar-
able to that observed in rats pretreated with only apo-
morphine. However, in experiment 3·, the concurrent 
administration of the D 1 selective dopamine receptor 
antagonist, SCH 23390, blocked both the: expression and 
the development of behavioral sensitization to apomor-
phine. Rats given both SCH 23390 and apomorphine in 
this experiment responded to a subsequent challenge 
dose of apomorphine in a manner similar to rats pre-
treated with only vehicle. These data suggest, of course, 
that the development of behavioral sensitization to apo-
morphine is mediated by dopamine D 1 receptor stimula-
tion. 
In agreement with these findings, Vezina and Stewart 
(1989; Stewart and Vezina 1989) have recently reported 
that although both D 1 and D 2 selective antagonists 
blocked the acute locomotor activating effects of am-
phetamine, only the D 1 receptor antagonist SCH 23390 
blocked the development of behavioral sensitization to 
amphetamine. Thus, like apomorphine, the development 
of behavioral sensitization to amphetamine appears to be 
related to D 1 receptor stimulation. Based upon both 
behavioral and electrophysiological data, other research-
ers have also concluded that repeated dopamine D 1 re-
ceptor stimulation may be the crucial factor neccessary 
for the induction of agonist-induced behavioral sensitiza-
tion (e.g., Braun and Chase 1988; Criswell et al. 1989; 
Henry and White 1989). But, as noted previously, not all 
investigators share this view (e.g., Levy et al. 1988). Peris 
and Zahniser (1989), for example, found that the augmen-
tation in amphetamine-induced 3H-dopamine release from 
striatal slices observed after a single pretreatment with 
cocaine could be blocked by either the D1 selective an-
tagonist, SCH 23390, or the D 2 selective antagonist, 
sulpiride. Similarly, Ujike et al. (1989) reported that the 
augmentation of locomotor activity and stereotypic be-
havior observed in rats following repeated meth-
amphetamine administration was blocked by concurrent 
treatments with either SCH 23390 or tJie D 2 antagonist, 
YM 09151-2. These results, of course, implicate both D 1 
and D 2 receptors in the development of behavioral sen-
sitization. At present, the basis for these discrepancies is 
unknown. Since · apomorphine, amphetamine, and co-
caine enhance dopaminergic activity through different 
mechanisms, it is possible that the neurochemical mech-
anisms underlying the development of behavioral sen-
sitization to each of these drugs may differ (cf Rowlett 
et al. 1991). However, it is not clear why different mech-
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anisms would mediate the development of behavioral 
sensitization to amphetamine and methamphetamine (cf 
Stewart and Vezina 1989; Ujike et al. 1989), since these 
drugs have similar mechanisms of action. This latter 
discrepancy is probably related to the differences in be-
havioral measures and/or the use of different selective 
antagonists among the studies. 
Several hypotheses have been proposed to account for 
the development of behavioral sensitization to dopamine 
agonists, including conditioning, autoreceptor tolerance, 
and an augmented agonist-induced release of dopamine 
(see Robinson and Becker 1986). The present results are 
inconsistent with each of these views. A conditioning 
explanation of behavioral sensitization, for example, sug-
gests that the progressive increase in apomorphine-
induced locomotor activity is related to the development 
of a conditioned locomotor activity response to the en-
vironmental stimuli associated with drug exposure. But 
in the present study, behavioral sensitization still de-
veloped to apomorphine in experiment 2 even though the 
activating effects of repeated apomorphine treatments 
were completely blocked by sulpiride during the training 
phase. Although this finding alone does not completely 
rule out the involvement of conditioning mechanisms, it 
is consistent with other work which suggests that behav-
ioral sensitization to apomorphine develops through 
both associative and nonassociative processes (cf Gold et 
al. 1988; Mattingly et al. 1988; Mattingly and Gotsick 
1989). 
The autoreceptor tolerance explanation of behavioral 
sensitization suggests that dopamine autoreceptors 
which appear to be inhibitory with respect to locomotor 
activity, become subsensitive with repeated exposure to 
non-selective agonists such as apomorphine and am-
phetamine. Thus, with repeated agonist treatments the 
inhibitory effects of autoreceptor stimulation on dopa-
mine synthesis, release, and firing rate progressively de-
crease and consequently, agonist-induced locomotor ac-
tivity increases (see Robinson and Becker 1986, for re-
view). In the present study, doses of the D2 antagonist 
sulpiride large enough to block both pre- and post-
synaptic D 2 receptors (cf Vezina and Stewart 1989), did 
not prevent the development of behavioral sensitization. 
Moreover, the dose of the D, receptor antagonist SCH 
23390 which prevented the development of behavioral 
sensitization in experiment 3, does not interact with 
dopamine autoreceptor function (Lappalainen et al. 
1990). Thus, although a significant amount of evidence 
suggests that autoreceptors do become less sensitive with 
repeated agonist treatments, autoreceptor tolerance 
alone cannot account for the development of behavioral 
sensitization (see Ackerman and White 1989; Braun and 
Chase 1988; Mattingly et al. 1988; Vezina and Stewart 
1989). 
Finally, much recent evidence suggests that repeated 
amphetamine treatments result in an augmented am-
phetamine-induced release of dopamine (Kuzcenski and 
Segal 1988, 1989; Robinson et al. 1988) which coincides 
with the development of behavioral sensitization to am-
phetamine. Similarly, the development of behavioral sen-
sitization to cocaine appears to be related to an increase 
in extracellular dopamine levels in the nucleus accum-
bens (Kalivas and Duffy 1990). But while these presynap-
tic effects may account for the development of behavioral 
sensitization to indirect dopamine agonists such as am-
phetamine and cocaine, which exert their effects primari-
ly by inducing the release and/or blocking the re-uptake 
of dopamine, these presynaptic effects cannot explain the 
development of sensitization to direct dopamine receptor 
agonists such as apomorphine (cf Braun and Chase 1988; 
Zahniser et al. 1988; Vaughn et al. 1990). At present, the 
only presynaptic effect reported which may be related to 
the development of sensitization to apomorphine is an 
increase in steady-state dopamine synthesis (Vaughn et 
al. 1990; Rowlett et al. 1991). 
In conclusion, the present results clearly indicate that 
the expression of dopamine agonist-induced behavioral 
effects requires some minimal level of stimulation of both 
D 1 and D2 dopamine receptors. In contrast, the develop-
ment of behavioral sensitization to apomorphine appears 
to require the repeated stimulation of only the D 1 recep-
tor. This finding with apomorphine is consistent with 
recent work with amphetamine. Finally, the results of the 
present experiments are inconsistent with conditioning 
and autoreceptor tolerance explanations of apomor-
phine-induced behavioral sensitization. 
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Abstract. The non-selective excitatory amino acid an-
tagonist kynurenic acid, which does not readily cross the 
blood-brain barrier, dose-dependently attenuated the be-
havioral signs of naltrexone-precipitated withdrawal in 
morphine-dependent rats following both intra ventricular 
and subcutaneous administration. However, intraven-
tricular and subcutaneous administration of kynurenic 
acid had different effects on individual withdrawal be-
haviors. Moreover, single unit recordings in anesthetized 
animals showed that intraventricular, but not sub-
cutaneous, kynurenic acid administration attenuated the 
withdrawal-induced increased firing of locus coeruleus 
neurons. These studies indicate that: (1) both central and 
peripheral excitatory amino acid receptors may play an 
important role in opiate withdrawal; and (2) excitatory 
amino acid antagonist treatments might be developed to 
reduce opiate abstinence symptoms in man. 
Key words: Kynurenic acid - Locus coeruleus- Excitato-
ry amino acid - Morphine - Opiate withdrawal 
The mechanism of opiate withdrawal is not completely 
understood. In man, opiate withdrawal is characterized 
by nausea, anxiety, insomnia, hot and cold flashes, mus-
cle aches, perspiration, diarrhea, and craving for the drug 
(Kolb and Himmelsbach 1938). A variety of neurotrans-
mitter systems have been hypothesized to play a role in 
opiate withdrawal including the brain noradrenergic sys-
tem (see Redmond and Krystal 1984). The role of the 
brain noradrenergic system in opiate withdrawal is sup-
ported in part by the finding that the noradrenergic cells 
of the locus coeruleus (LC) greatly increase their activity 
during antagonist-precipitated withdrawal (Aghajanian 
1978; Valentino and Wehby 1989) and that this increased 
activity correlates temporally with withdrawal behavior 
(Rasmussen et al. 1990). In addition, clonidine, an al-
pha-2 agonist, decreases the activity of LC neurons 
Ojj'print requests to: K. Rasmussen 
during morphine withdrawal (Aghajanian 1978), sup-
presses withdrawal behaviors after direct infusion into 
the LC (Taylor et al. 1988), and is used to minimize 
opiate-withdrawal symptoms in man (Gold et al. 1978). 
However, ST-91, an alpha-2 agonist that does not readi-
ly cross the blood-brain barrier, can also suppress mor-
phine-withdrawal behaviors after either peripheral or 
central administration, indicating that both central and 
peripheral noradrenergic systems play a role in the ex-
pression of many opiate-withdrawal behaviors (Taylor 
et al. 1988). 
Kynurenic acid, a naturally occurring metabolite of 
tryptophan that is found in brain tissue (Stone et al. 
1987), is a non-selective excitatory amino acid antagonist 
(Perkins and Stone 1982) that does not readily cross the 
blood-brain barrier (Swartz et al. 1990). Recent studies 
have shown that intra ventricular administration of kyn-
urenic acid greatly attenuates the withdrawal-induced 
activation of LC neurons (Rasmussen and Aghajanian 
1989; Tung et al. 1990). Therefore, the present study was 
conducted to evaluate the effects of intraventricular ad-
ministration of kynurenic acid on morphine-withdrawal 
behaviors, and further, to evaluate the effects of systemic 
administration of kynurenic acid on both the behavioral 
signs of morphine withdrawal and the withdrawal-
induced increase in firing of LC neurons. 
Materials and methods 
Opiate dependence was induced in male Sprague-Dawley rats 
(Charles River, 250-350 g) by the subcutaneous pellet implantation 
method (Jlay el al. 1969; Blassig et al. 1973). Under halathane 
anesthesia, animals were implanted with either morphine pellets 
(NIDA: 75 mg morphine base) or sham pellets. One pellet was 
implanted daily for 2 days. Withdrawal was induced 48 h after the 
last pellet implantation; the pellets were removed under halothane 
anesthesia 2-3 h before precipitating withdra\val. Withdrawal was 
induced by administering the opiate antagonist naltrexone HCI 
(IO mg/kg; Sigma) subcutaneously (SC). 
The severity and time course of opiate withdrawal was assessed 
as described previously (Rasmussen et al. 1990). Briefly, animals 
were studied in pairs in.clear plexiglass cages (11 in x 7 in x 5 in) and 
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